Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

Abstract

Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.

Atomoxetine treatment of ADHD in Tourette Syndrome: Reduction in motor cortex inhibition correlates with clinical improvement

“…Third, with regard to generalizability, this study's sample was small and limited to TS+ADHD children. Although, the clinical response rate in this study is consistent with those in large clinical trials of ATX in children with tics (Allen et al, 2006) and without tics (Michelson et al, 2002), it would be premature to generalize the results from this study to non-TS ADHD. In addition, this TS sample had a somewhat lower SICI ratio than our prior cohorts, for unclear reasons.…”

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder

“…Placebo-treated patients showed very little improvement beyond this 3-week time point. At endpoint, the lsmean decrease in the ADHD-RS score for placebo-treated patients was 6.3 points, a change very similar to that seen in other placebo-controlled atomoxetine trials that did not include concomitant psychoeducation: In five of six placebo-controlled studies, each with a duration of 6-9 weeks and using investigator-rated ADHD-RS, the mean change in the placebo-treated group varied between 5.5 and 7.0 points [11][12][13][14], whereas corresponding decreases in mean ADHD-RS scores in the atomoxetine-treated groups of these studies varied between 12.8 and 16.7 points; however, this was still well below the lsmean reduction of 19.0 points observed in the present study.…”

“…Administered once-daily in the morning, it provides continuous symptom relief that lasts not only into the evening hours but also into the morning hours [11]. Atomoxetine was proven to be a well-tolerated and efficacious treatment for ADHD in the first six acute placebo-controlled studies, in which it was always statistically superior to placebo [11][12][13][14][15]. Currently it presents by far the most extensively studied pharmacotherapeutic drug in clinical trials on children with ADHD [16].…”

Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study

“…At baseline, this group of children was found to have moderate to severe symptoms of ADHD and levels of impairment, together with significant levels of co-existing problems as assessed by both physicians (ADHD-RS-IV, CGI-S and CGAS) and parents (SDQ). The mean ADHD-RS-IV score (35.8) whilst relatively high is somewhat lower than that seen in recent clinical trials of ADHD medication, where scores were in the range of 37 to 41 [24,25]. The mean CGI-S score (4.4) suggests that most patients were rated as moderately or severely ill and the mean CGAS score (55.2) fell well below the cut-off for significant clinical impairment.…”